Form 4: Charles River Laboratories Director Kemps-Polanco Reports Acquisition of Shares and Stock Options

Director Reshema Kemps-Polanco reports acquiring common stock and stock options in Charles River Laboratories International, Inc.

Summary

• Reshema Kemps-Polanco, a director of Charles River Laboratories International, Inc. (CRL), filed a Form 4 indicating changes in beneficial ownership.
• On May 13, 2024, Kemps-Polanco acquired 559 shares of common stock at $228.41 per share.
• Additionally, 285 shares were acquired in lieu of director service fees for the term commencing May 8, 2024, also at $228.41 per share.
• Kemps-Polanco also acquired 1,311 stock options with an exercise price of $228.41.
• Following these transactions, Kemps-Polanco directly owns 1,014 shares of common stock and 1,311 stock options.
• The restricted stock units and stock options vest upon the earlier of May 13, 2025, or the business day prior to the company's next annual meeting of shareholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting of the acquired securities is tied to future dates and the company's annual meeting.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company.

Comparison to Industry Standards

• Director compensation packages often include stock options and restricted stock units to align the interests of directors with those of shareholders.
• The vesting schedules for these equity grants are typically tied to continued service and performance milestones, which is consistent with industry standards.
• Comparing the size and terms of these grants to those of directors at comparable companies (e.g., other contract research organizations like Labcorp or ICON) would provide further context.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as they reflect insider confidence.

Key Dates